This company has been marked as potentially delisted and may not be actively trading. NASDAQ:NLSPW NLS Pharmaceutics (NLSPW) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About NLS Pharmaceutics Stock (NASDAQ:NLSPW) Get NLS Pharmaceutics alerts:Sign Up Key Stats Today's Range$0.01▼$0.0250-Day Range$0.01▼$0.0352-Week Range$0.00▼$0.07Volume130,055 shsAverage Volume49,507 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview NLS Pharmaceutics Ltd. is a clinical-stage specialty pharmaceutical company headquartered in Zurich, Switzerland. The company focuses on the development and commercialization of innovative drug delivery systems that enhance the performance of existing small-molecule and peptide therapies. NLS Pharmaceutics employs a proprietary lipid nanoparticle platform to formulate products aimed at improving solubility, bioavailability and patient adherence. Through its core technology, NLS Pharmaceutics creates advanced formulations designed for central nervous system, dermatology and ophthalmology indications. By leveraging controlled-release and targeted-delivery approaches, the company seeks to reduce dosing frequency, minimize side effects and optimize therapeutic profiles. Its research and development activities encompass preclinical testing, formulation optimization and human clinical trials. The company’s pipeline includes multiple clinical-stage candidates, among them proprietary formulations of established compounds for migraine prevention, sleep disorders and other CNS indications. NLS Pharmaceutics collaborates with academic institutions and commercial partners to advance its product candidates through regulatory pathways in Europe, North America and additional markets. By combining novel delivery solutions with well-characterized active pharmaceutical ingredients, the company aims to bring differentiated therapies to patients and healthcare providers globally.AI Generated. May Contain Errors. Read More Receive NLSPW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NLS Pharmaceutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NLSPW Stock News HeadlinesNLS Pharmaceutics Amends Merger Agreement with KadimastemJune 6, 2025 | tipranks.comNLS Pharmaceutics Extends Merger Agreement with KadimastemMay 5, 2025 | tipranks.comTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in modern history - larger than Paul Tudor Jones' Black Monday bet and Michael Burry's $700 million Big Short. While most investors chase AI stocks, insiders including Ray Dalio and Tudor Jones have quietly repositioned. The last comparable shock sent certain stocks up 2,464%, 2,778%, and even 13,000% - turning a $10,000 stake into over $1.3 million. Dr. Eifrig has identified one stock at the center of this story and released a free broadcast to help investors act before the window closes.July 14 at 1:00 AM | Stansberry Research (Ad)NLS Pharmaceutics Secures $3 Million Financing and $25 Million Equity FacilityMarch 31, 2025 | tipranks.comNLS Pharmaceutics Shareholders Approve Meeting AgendaJanuary 7, 2025 | tipranks.comNLS Pharmaceutics Calls Extraordinary Meeting for Major Capital RestructuringDecember 23, 2024 | tipranks.comNLS Pharmaceutics Ltd. (NLSP)May 19, 2024 | finance.yahoo.comNLS Pharmaceutics Ltd. (NLSPW)May 17, 2024 | finance.yahoo.comSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NLSPW CIK1783036 WebN/A Phone41-44-512-21-50FaxN/AEmployees6Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:NLSPW) was last updated on 7/14/2026 by MarketBeat.com Staff. From Our PartnersTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThey told you not to miss this oneThe largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...Thor Metals | SponsoredForget SpaceX, this is Elon’s Next BreakthroughJeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI pa...Brownstone Research | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
